My brother-in-law asked me a question I have not been able to forget: would you pay $100,000 for another 10 minutes of life?

The question came from his neighbor, who has stage 4 pancreatic cancer. My brother-in-law is also a cancer patient. So far, the disease has cost him a kidney and possibly part of his liver, but he is still alive. Several people in my circle are living with cancer.

Their experiences point to a question medicine alone cannot answer: “When survival depends on treatment, when does care become business?“

Later in this article, I use the term “financial toxicity,” the phrase medical researchers use for the severe financial distress, debt, and lifestyle disruption caused by treatment costs. In oncology, it is treated as a literal side effect because it can affect recovery, mental well-being, and even survival.

As of 2025, 18.6 million people in the United States were living with a history of cancer, and just over two million new cases were projected for the year. Cancer does not affect the largest share of patients, but it concentrates unusually high costs through specialized drugs, surgeries, imaging, hospital stays, and long-term monitoring. In practical terms, the country sees four new cancer diagnoses per minute.

A large share of healthcare spending in the United States goes toward chronic and mental health conditions. Public-health agencies also point to a short list of modifiable risk factors – such as smoking, poor nutrition, physical inactivity, and excessive alcohol use – as major contributors to preventable disease. The exact savings from changing those behaviors are debated, but the broader point remains: prevention and better baseline health could reduce both suffering and cost.

Cancer patients often face medical expenditures several times higher than those of people without cancer. That burden is not driven by a single test or drug but by the cumulative cost of surgery, radiation, infusion therapy, hospitalizations, advanced diagnostics, surveillance, and pharmaceuticals, often delivered over months or years.

Over the last two decades, major health insurers have generated very large cumulative profits, although the exact total depends on which companies and time periods are included. That reality helps explain why the question that opened this article feels less hypothetical than it should.

A large share of Americans live paycheck to paycheck, which makes a major medical event financially destabilizing even before the first large bill arrives. Research on financial toxicity points to the same conclusion: a cancer diagnosis can create a disproportionate, sometimes catastrophic, economic burden, especially for lower- and middle-income households.

~ The Multi-Billion Dollar Business of Cancer Care ~

The financial burden of cancer is only one part of the story. The other is structural: cancer care now sits inside one of the largest and fastest-growing sectors in modern healthcare. Depending on the source and what is included in the definition of the market, recent estimates place the global oncology market in the low hundreds of billions of dollars today, with projections rising sharply over the next decade. That growth is driven by high-cost therapies, consolidation, and the hard economic reality that patients facing life-threatening disease do not have the luxury of ordinary consumer choice.

That raises an uncomfortable question: when a disease sustains such a large commercial ecosystem, how do we ensure that incentives remain aligned with prevention, affordability, and patient well-being?

The “Buy-and-Bill” Reimbursement System
A distinctive financial mechanism in U.S. outpatient cancer care is the “Buy-and-Bill” model used by private oncology clinics.

– The Procurement Process: Independent oncologists purchase expensive chemotherapy and immunotherapy drugs directly from wholesalers. They manage clinic inventory, administer medications to patients, and then bill the patient’s insurance provider.

– The Financial Incentive: Clinics generate revenue through reimbursement for provider-administered drugs, and critics of the model argue that it can create incentives that are not always perfectly aligned with lower-cost care. The magnitude of that incentive varies by payer, contract structure, and site of service.

Consolidation and Mega-Networks

The independent oncology landscape is shifting as community practices merge into large health systems and corporate networks, increasing consolidation across cancer care.

– Hospital Acquisitions: Large healthcare systems and private equity firms continue to acquire community oncology practices. Critics argue that this can expand access to discounted outpatient drugs through the federal 340B Drug Pricing Program, while supporters contend that 340B savings help safety-net providers stretch resources and fund additional services.

– Insurance Alliances: To manage escalating oncology costs, major health insurers are partnering with specialized care-management firms. These corporate alliances aim to standardize treatments, enforce strict clinical guidelines, and cap runaway specialty spending.

The Patient Impact: “Financial Toxicity”

Because cancer care is a high-cost enterprise, the financial fallout for consumers is significant. Medical researchers use the term financial toxicity to describe the economic burden placed on patients and families when treatment costs overwhelm normal life.

– Asset Depletion: Research has found that a substantial share of newly diagnosed cancer patients over age 50 experience severe asset loss within two years of diagnosis.

– The Debt Burden: Recent survey and research summaries suggest that cancer-related medical debt is common, with many patients and survivors reporting thousands of dollars in outstanding balances even when they were insured at the time treatment occurred.

– Clinical Outcomes: Research has also linked severe financial distress, including bankruptcy, with worse treatment adherence and poorer outcomes among some cancer patients.

Where does this leave the couple about to retire if a cancer diagnosis wipes out years of savings? At a minimum, it exposes how poorly many households are protected from the financial shock of serious illness.

Viewed structurally, the modern cancer care system operates as both a healing enterprise and a revenue engine. The doctors, nurses, and researchers on the ground may be motivated by compassion, but the corporate framework surrounding them is built around margins, growth, and market share. That tension lies at the center of the entire system.

Why does it so often feel as though the system is “about money”?

Three structural realities help explain why.

The Inelastic Demand Loop
In a standard economic market, if a product becomes too expensive, consumers can delay or walk away. In oncology, the choice is often far narrower because treatment may be tied directly to survival or quality of life. That dynamic gives pharmaceutical companies, hospital systems, and specialty clinics unusual pricing power compared with ordinary consumer markets.

Profit Incentives Drive the Science
The direction of cancer research is shaped in part by where the strongest financial return on investment can be achieved, alongside scientific opportunity, regulatory pathways, and clinical need.

– The Treatment vs. Prevention Bias: Corporate incentives are often stronger for patent-protected therapies and proprietary technologies than for preventive lifestyle interventions or low-cost screening methods, even when prevention could reduce suffering and long-term expense.

– Patent Protection: The system often rewards complex, high-cost therapies that can be protected for years, creating powerful incentives to develop treatments with strong commercial potential.

Structurally Misaligned Goals
For a patient, success means eradicating disease at the lowest possible personal cost. For a publicly traded healthcare corporation, success is often measured in quarter-over-quarter revenue growth.

– When hospitals buy up local clinics to expand access to 340B pricing discounts, or when clinics rely on the “Buy-and-Bill” markup to stay solvent, the institution’s financial survival can become tied to the volume and price of the drugs it dispenses.

– The system tends to generate more revenue from ongoing treatment than from prevention alone. Structurally, that can favor long, high-cost treatment pathways over the quieter economics of keeping people healthy before they need intensive care.

While individual healthcare workers often act out of empathy and professional duty, they operate within an economic system that can turn a life-threatening disease into a highly profitable commercial enterprise.

~ How Patients Can Protect Themselves ~

If this is the system we have, the practical question is how patients protect themselves within it. The answer is to move from passive recipient to active manager of care.

When facing cancer care, the volume of information can make decision-making feel impossible. The best protection is to approach the process not as a passive recipient of instructions but as the chief executive of your own care team.

A practical way to protect your health, autonomy, and finances is to work through the decisions in a clear sequence:

1. Pause and Establish the Timeline
Except in rare medical emergencies, such as acute leukemia or spinal cord compression, patients usually have days or weeks to gather information and weigh options.

– Resist the Pressure to Rush: Taking 10 to 14 days to research, seeking a second opinion, and processing your emotions will not compromise your treatment’s effectiveness.

– Establish the True Urgency: Ask your physician directly, “What is the exact medical consequence of waiting two full weeks to start this specific protocol?”

2. Secure a Specialized Second Opinion
A second opinion is standard practice in oncology. Reputable oncologists expect it, and many insurance plans routinely cover it.

– Seek an Academic Specialist: If your initial diagnosis is made at a small community hospital, seek a second opinion at a major academic research institution or an NCI-Designated Cancer Center (National Cancer Institute). These centers have highly specialized oncologists who treat only your specific type of cancer, rather than general oncologists who treat a wide range of cancers.

– Confirm the Pathology: Second opinions and expert pathology review can meaningfully refine a diagnosis or treatment plan, especially when cases are reviewed at specialized cancer centers. The exact rate varies widely by cancer type, institution, and what is being re-evaluated.

3. Ask the Four “North Star” Questions
Before agreeing to any surgery, chemotherapy regimen, or radiation plan, ask your care team these specific questions to ensure the treatment aligns with your personal values:

a) “What is the ultimate goal of this treatment?” (Curative vs. Palliative): Is the intent to permanently eradicate the cancer, or to shrink the tumor to manage pain and extend life by a few months?

b) “What is the quantitative benefit?” Do not accept vague phrases like “this drug works well.” Ask for numbers: “By what exact percentage does this drug increase my chance of survival or disease-free remission compared with no treatment?”

c) “What is the trade-off for my quality of life?“: What are the daily side effects? Will I be able to work, walk independently, or care for myself during active therapy?

d) “Are clinical trials available?” Clinical trials are no longer a “last resort.” In modern oncology, they often offer free, early access to cutting-edge immunotherapies that will become tomorrow’s standard of care.

4. Demand a Financial Toxicity Screening Upfront
Because cancer care costs can trigger severe financial stress, look at the price tag before the first medication is prepared in the pharmacy.

– Meet with a Financial Navigator: Before signing a treatment consent form, tell the clinic’s scheduling coordinator, “I need to meet with your hospital financial counselor or navigator to review my out-of-pocket maximums and co-pays for this drug regimen.”

– Request Alternative Care Sites: Ask whether your chemotherapy infusions can be administered at an independent, non-hospital community clinic rather than at a main hospital campus, which can reduce your out-of-pocket “facility fees” by thousands of dollars.

5. Build Your Multi-Disciplinary Support Team

Do not let a single doctor make every decision. A robust care structure should include overlapping specialists.

– The Clinical Lead: Your Medical Oncologist.

– The Quality-of-Life Lead: A Palliative Care Specialist. (Palliative care is not hospice; it is a medical specialty focused on managing pain, nausea, and treatment side effects from the day a serious illness begins. Its goal is to ease symptoms and improve quality of life, whether or not the underlying disease can be cured.

– The Practical Lead: A Medical Social Worker who can coordinate family medical leave paperwork (FMLA), disability claims, and local transportation services.

Finally, remember that this is about you or someone you love. It is your health, your money, and your future. You preserve the most control when you stay informed, ask direct questions, and refuse to hand over every decision without understanding the trade-offs.

In a system this costly and complex, informed support is not optional; it is part of survival.

‘The devil you say…‘

 

 

For the Amalgamated Heavy…

June 16, 2026

~ the Author ~
Charles R. Dickens Was Born in 1951, Is a Veteran of the Vietnam War, for Which He Volunteered, and the Great-Great Grandson of the Noted Author, Whose Name He Shares.

He Is a Fiercely Proud American, Who Still Believes This Is the Greatest Country on the Planet, With Which We’ve Lost Control and Certainly Our Direction. He Grew Up in Moderate Financial Surrounding; We’re Not Rich by Any Stretch, but Didn’t Go Hungry – His Incredibly Hard Working Father Saw to That. As Most From That Era, He Learned About Life From His Father, Whose Story Would Take Too Long to Tell, Other Than to Say That, He Is Also a Fiercely Proud American; A WWII and Korean War, Veteran Marine.

Charlie Was Educated in the Parochial System Which, Demanded That You Actually Learn Something, and Have Capability to Retain It Before You Advance. He Attended Several Universities in Pursuit of a Bachelor’s Degree, and Chased the Goose Further to a Master’s, and Has Retained Some Very Definite Ideas About Education in This Country.

in Addition, Charlie Is a Retired Blues Guitar and Vocalist – a Musician. This Was His Therapy Career. Nothing Brings Him as Much Joy as Playing Music, and He Wishes That He Could Make a Living at It… but Alas… Life Goes on!